U
NBSE

UBS’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

UBS’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$9K Sell
3
-46
-94% -$152K ﹤0.01% 8953
2014
Q2 		$187K Buy
+49
New +$184K ﹤0.01% 5217

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS's NBSE Position: Q3 2014 in Review

UBS increased its NeuBase Therapeutics, Inc. Common Stock (NBSE) stake by 25% in Q3 2014, buying an estimated $62.8K and bringing the position to 96 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

UBS first reported a position in NBSE in Q2 2013 and has held it in 6 quarters since. The position peaked at $935K in Q1 2014. 52 funds tracked by Wall St. Rank hold NBSE as of Q3 2014.

  • UBS held 96 shares of NeuBase Therapeutics, Inc. Common Stock worth $278K as of Q3 2014.
  • UBS bought 19 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $62.8K.
  • NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4844 holding.
  • UBS first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's NeuBase Therapeutics, Inc. Common Stock position peaked at $935K in Q1 2014.
  • 52 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.